Summary
In 2014 biochemist Jennifer Doudna of the University of California at Berkeley awoke from a nightmare that would shift the focus of her world-class scientific career. Two years earlier, with her colleague Emmanuelle Charpentier, now director of the Max Planck Unit for the Science of Pathogens in Berlin, Doudna had achieved one of the most stunning breakthroughs in the history of biology, becoming the first to use a process called CRISPR-Cas9 to alter the genetic makeup of living organisms. Their “gene-editing” tool would allow scientists to efficiently insert or delete specific bits of DNA with unprecedented precision.
But as applications related to modifying human genes were soon reported in the scientific literature, Doudna began to worry. In the dream, a colleague asked if she would help teach someone how to use CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats). She followed him into a room to be greeted by Adolph Hitler wearing a pig face. The nightmare reinforced her belief that public discussion of the technology was far behind the breakneck pace of its emerging applications. She feared a public backlash that would prevent beneficial forms of gene-editing research from moving forward.